Ticagrelor — Membership Pricing

Other medications in Heart & Cardiovascular

• Torsemide
• Trandolapril
• Treprostinil
• Triamterene
• Valsartan
• Verapamil
• Verapamil IV
• Vernakalant

What Ticagrelor is approved for (FDA label)

Ticagrelor tablet is a P2Y 12 platelet inhibitor indicated • to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) • to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events.

Source: Read the full FDA label on DailyMed. Label effective date: September 1, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Ticagrelor (FDA label)

WARNING: BLEEDING RISK • Ticagrelor tablets, like other antiplatelet agents, can cause significant, sometimes fatal bleeding (5.1, 6.1). • Do not use ticagrelor tablets in patients with active pathological bleeding or a history of intracranial hemorrhage (4.1, 4.2). • Do not start ticagrelor tablets in patients undergoing urgent coronary artery bypass graft surgery (CABG) (5.1, 6.1). • If possible, manage bleeding without discontinuing ticagrelor tablets. Stopping ticagrelor tablets increases the risk of subsequent cardiovascular events (5.2). WARNING: BLEEDING RISK See full prescribing information for complete boxed warning. • Ticagrelor tablets, like other antiplatelet agents, can cause significant, sometimes fatal bleeding. (5.1, 6.1) • Do not use ticagrelor tablets in patients with active pathological bleeding or a history of intracranial hemorrhage. (4.1, 4.2) • Do not start ticagrelor tablets in patients undergoing urgent coronary artery bypass graft surgery (CABG). (5.1, 6.1) • If possible, manage bleeding without discontinuing ticagrelor tablets. Stopping ticagrelor tablets increases the risk of subsequent cardiovascular events. (5.2)

Source: FDA prescribing information (DailyMed). Set ID: 557351f1-47b7-216d-e063-6394a90afb51. SPL document ID: 5a66211c-c575-e6e6-e063-6294a90a0a79. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Ticagrelor (FDA label)

Ticagrelor tablet 90 mg is supplied as a yellow, round, biconvex, film-coated tablets debossed with ‘522’ on one side and ‘L’ on other side. Ticagrelor tablet 60 mg is supplied as pink, round, biconvex, film-coated tablets debossed with “L 94” on one side and plain on other side. 60 mg and 90 mg tablets. (3)

Source: FDA prescribing information (DailyMed). Set ID: 557351f1-47b7-216d-e063-6394a90afb51. SPL document ID: 5a66211c-c575-e6e6-e063-6294a90a0a79. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Ticagrelor (FDA label)

The following adverse reactions are also discussed elsewhere in the labeling: Bleeding [see Warnings and Precautions (5.1)] Dyspnea [see Warnings and Precautions (5.3)] Most common adverse reactions (>5%) are bleeding and dyspnea. (5.1, 5.3, 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Alembic Pharmaceuticals Limited at 1-866-210-9797 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Ticagrelor has been evaluated for safety in more than 58,000 patients.

Source: FDA prescribing information (DailyMed). Set ID: 557351f1-47b7-216d-e063-6394a90afb51. SPL document ID: 5a66211c-c575-e6e6-e063-6294a90a0a79. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Ticagrelor (FDA label)

History of intracranial hemorrhage. (4.1) Active pathological bleeding. (4.2) Hypersensitivity to ticagrelor or any component of the product. (4.3) 4.1 History of Intracranial Hemorrhage Ticagrelor tablet is contraindicated in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population [see Clinical Studies (14.1, 14.2)]. 4.2 Active Bleeding Ticagrelor tablet is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)]. 4.3 Hypersensitivity Ticagrelor tablet is contraindicated in patients with hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product .

Source: FDA prescribing information (DailyMed). Set ID: 557351f1-47b7-216d-e063-6394a90afb51. SPL document ID: 5a66211c-c575-e6e6-e063-6294a90a0a79. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Ticagrelor (FDA label)

Dyspnea was reported more frequently with ticagrelor than with control agents in clinical trials. Dyspnea from ticagrelor is self-limiting. (5.3) Severe Hepatic Impairment: Likely increase in exposure to ticagrelor. (5.5) Laboratory Test Interference: False negative platelet functional test results have been reported for Heparin Induced Thrombocytopenia (HIT). Ticagrelor is not expected to impact PF4 antibody testing for HIT. (5.7) 5.1 Risk of Bleeding Drugs that inhibit platelet function including ticagrelor increase the risk of bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)]. Patients treated for acute ischemic stroke or TIA Patients at NIHSS >5 and patients receiving thrombolysis were excluded from THALES and use of ticagrelor in such patients is not recommended. 5.2 Discontinuation of Ticagrelor in Patients Treated for Coronary Artery Disease Discontinuation of ticagrelor will increase the risk of myocardial infarction, stroke, and death in patients being treated for coronary artery disease.

Source: FDA prescribing information (DailyMed). Set ID: 557351f1-47b7-216d-e063-6394a90afb51. SPL document ID: 5a66211c-c575-e6e6-e063-6294a90a0a79. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Ticagrelor (FDA label)

Avoid use with strong CYP3A inhibitors or CYP3A inducers. (7.1, 7.2) Opioids: Decreased exposure to ticagrelor. Consider use of parenteral anti-platelet agent. (7.3) Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects. (7.4) Rosuvastatin plasma concentrations may increase. Monitor for statin-related adverse effects. (7.4) Monitor digoxin levels with initiation of or any change in ticagrelor. (7.5) 7.1 Strong CYP3A Inhibitors Strong CYP3A inhibitors substantially increase ticagrelor exposure and so increase the risk of dyspnea, bleeding, and other adverse events. Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [ see Clinical Pharmacology (12.3) ] . 7.2 Strong CYP3A Inducers Strong CYP3A inducers substantially reduce ticagrelor exposure and so decrease the efficacy of ticagrelor.

Source: FDA prescribing information (DailyMed). Set ID: 557351f1-47b7-216d-e063-6394a90afb51. SPL document ID: 5a66211c-c575-e6e6-e063-6294a90a0a79. Label effective date: September 1, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.